Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics, Inc. announced the grant of inducement stock options for 3,600 shares to two new non-executive employees on February 19, 2026. These options have an exercise price of $2.85, matching the closing price on the grant date, and vest over a three-year period. The grants were made under the company's Amended and Restated 2021 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4).
Iovance Biotherapeutics Inc. (IOVA) Builds Momentum With New Trial Data
Iovance Biotherapeutics Inc. (IOVA) announced new trial data affirming a best-in-class profile for its commercial T cell therapy, Amtagvi, designed for advanced melanoma patients. The therapy showed impressive response rates, including a 44% overall response rate and 52% in earlier lines of therapy, positioning the company to address an unmet medical need in advanced melanoma treatment. The results highlight the potential of Amtagvi to offer better outcomes for patients through personalized cancer treatments that leverage the body's own immune system.
Principal Financial Group Inc. Has $6.54 Million Position in Iovance Biotherapeutics, Inc. $IOVA
Principal Financial Group Inc. significantly reduced its stake in Iovance Biotherapeutics (NASDAQ:IOVA) by 34.5% in the third quarter, ending the period with 3,013,753 shares valued at approximately $6.54 million. Despite this, other institutional investors increased their holdings, and the company has received mixed analyst ratings, with a consensus "Hold" rating and a price target of $10.50. Iovance Biotherapeutics is a clinical-stage biotech focused on tumor-infiltrating lymphocyte (TIL) immunotherapies for solid tumors.
April 2nd Options Now Available For Iovance Biotherapeutics (IOVA)
New options contracts for Iovance Biotherapeutics Inc (IOVA) expiring on April 2nd have become available. A specific put contract at the $2.50 strike price is highlighted, offering an attractive entry point for investors at a potential cost basis of $2.45, given its current trading price of $2.60 and an 83% chance of expiring worthless. This strategy, termed "YieldBoost," could yield a 2.00% return on the cash commitment, or 14.91% annualized, if the contract expires without being exercised.
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
Iovance Biotherapeutics will host a conference call and live audio webcast on Tuesday, February 24, 2026, at 8:30 a.m. ET to release its fourth quarter and full-year 2025 financial results and provide corporate updates. The company specializes in developing tumor-infiltrating lymphocyte (TIL) therapies for cancer, including Amtagvi®, the first FDA-approved T cell therapy for a solid tumor indication. The webcast will be accessible via the Investors section of their website, IR.Iovance.com.
The Bull Case For Iovance Biotherapeutics (IOVA) Could Change Following New Amtagvi Real-World Data - Learn Why
Iovance Biotherapeutics recently reported promising real-world data for its Amtagvi therapy for advanced melanoma, showing high response rates, yet the company also highlighted significant regulatory, manufacturing, and commercialization risks. While the new data could strengthen the commercial outlook and reaffirm revenue guidance, investors must consider potential delays in international approvals and pricing pressures. The article suggests that despite strong clinical results, the company's financial fragility, high operating costs, and intense competition remain critical factors in its investment narrative.
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
Iovance Biotherapeutics, Inc. will host a conference call and live audio webcast on Tuesday, February 24, 2026, at 8:30 a.m. ET to announce its fourth quarter and full year 2025 financial results and provide corporate updates. The company is a biotechnology firm focused on developing and delivering tumor infiltrating lymphocyte (TIL) therapies for cancer patients, including its FDA-approved Amtagvi® for solid tumors.
Iovance Biotherapeutics to Host Conference Call for Q4 and Full Year 2025 Financial Results on February 24, 2026
Iovance Biotherapeutics announced it will host a conference call and live audio webcast on February 24, 2026, at 8:30 a.m. ET to discuss its fourth-quarter and full-year 2025 financial results and corporate updates. The company, known for its FDA-approved T-cell therapy Amtagvi® for solid tumors, will make the webcast available for one year on its investor relations website. This call will provide insights into its ongoing operations and commitment to cell therapy innovation.
Does The Recent Share Price Slump Make Iovance Biotherapeutics (IOVA) Look More Attractive?
Iovance Biotherapeutics (IOVA) has experienced a significant share price decline, including a 59.9% drop over the last year. Despite this slump, Simply Wall St's valuation checks suggest the stock is undervalued, scoring 5 out of 6 on key measures. A Discounted Cash Flow (DCF) analysis estimates an intrinsic value of US$27.19 per share, indicating a 91.3% undervaluation compared to its recent price of US$2.36, while its Price/Sales ratio also screens as undervalued.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Rating of "Hold" from Brokerages
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has received a consensus "Hold" rating from fourteen brokerages, with an average one-year price target of $10.50. The company reported a Q3 EPS of -$0.25 (beating estimates) on revenues of $67.46 million (missing estimates) and has significant institutional ownership. Analysts have adjusted price targets, and major institutional investors have recently increased their stakes in the biotechnology firm.
Iovance Biotherapeutics (IOVA) Gives Update on Revenue Guidance, Lung Cancer Cure
Iovance Biotherapeutics (IOVA) provided an update on its revenue guidance and pipeline. The company expects to meet its $250-$300 million revenue guidance for 2025 from Amtagvi sales, projecting peak sales of up to $1 billion for the melanoma treatment. Additionally, Iovance announced that Lifileucel, a lung cancer treatment in development, has a commercial opportunity potentially seven times larger than Amtagvi and is expected to launch in the second half of 2027.
Barclays Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)
Barclays analyst Etzer Darout has reiterated a Buy rating for Iovance Biotherapeutics (IOVA) with a price target of $10.00. This comes as Iovance reported increased quarterly revenue of $67.46 million, though it also marked a GAAP net loss of $91.25 million, compared to previous figures of $58.55 million revenue and an $83.54 million net loss. Other analysts from TipRanks had differing views, with Google's Google Biotechnology also issuing a Buy, while OpenAI reiterated a Hold rating on the stock.
Iovance Biotherapeutics Announces Promising Real-World Data for Amtagvi® in Advanced Melanoma Treatment
Iovance Biotherapeutics announced real-world data for its FDA-approved T cell therapy, Amtagvi® (lifileucel), showing a 44% objective response rate and 73% disease control rate in advanced melanoma patients. This data, presented at a major medical meeting, indicates improved outcomes compared to earlier clinical trials, especially for patients treated earlier in their therapy. The company continues to confirm Amtagvi's benefits in ongoing clinical trials to address the significant unmet medical need in metastatic melanoma.
Melanoma cell therapy shows 52% response when used earlier
Iovance Biotherapeutics reported real-world data for its cell therapy Amtagvi (lifileucel) in advanced melanoma, showing a 44% overall objective response rate and 73% disease control rate in 41 evaluable patients. The response rate increased to 52% when Amtagvi was used earlier in treatment, after two or fewer prior therapies, compared to 33% for those with three or more prior lines. This data reinforces the therapy's clinical profile, complementing its prior accelerated FDA approval and ongoing Phase 3 trials.
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics announced the grant of inducement stock options covering 43,150 shares to four new non-executive employees on December 18, 2025. These awards were made under the company's Amended and Restated 2021 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $2.46 and vest over a three-year period, tied to continued employment.
Assessing Iovance Biotherapeutics (IOVA) Valuation As It Transitions To Commercial Stage With First Product Launch Plans
Iovance Biotherapeutics (IOVA) is transitioning to a commercial-stage biotech with plans for its first product launch, leading to a new focus on its valuation. Despite a recent 45.86% 90-day share price return, the company has experienced a 94.78% loss over five years, indicating past volatility. The article highlights a narrative fair value of $8.35 against its current trading price of $2.64, suggesting it is significantly undervalued, contingent on successful product launches and operational streamlining.
Former Iovance CEO Maria Fardis lands at AirNexis with $200 million - Bizwomen
Former Iovance CEO Maria Fardis has joined AirNexis Therapeutics, a new biotech company focusing on COPD, after raising over $1 billion for Iovance. AirNexis has secured $200 million in Series A funding led by Frazier Life Sciences. Fardis is well-known for her work at Iovance, which included leading the development of a cancer therapy approved by the FDA in 2024.
Former Iovance CEO Maria Fardis lands at AirNexis with $200 million - Bizwomen
Maria Fardis, former CEO of Iovance Biotherapeutics, has been appointed CEO of AirNexis Therapeutics, a new Palo Alto-based drug company. AirNexis has emerged with $200 million in Series A funding to focus on developing a drug for chronic obstructive pulmonary disease (COPD). Fardis is known for her previous work at Iovance, where she raised over $1 billion and achieved FDA approval for Amtagvi, a cancer treatment.
Financial Investigation Sparks Potential Reforms at Iovance Biotherapeutics
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) is currently under investigation by the law firm Johnson Fistel regarding its corporate governance, internal controls, and executive oversight. Amidst these concerns, the company's stock has declined by 7.05%. This probe could lead to significant reforms, potentially impacting investor confidence and Iovance's market position within the biotech sector, despite the company's stable short-term financial health evidenced by a strong current ratio.
Iovance Biotherapeutics Sets Stage for Global TIL Leadership with Stock Induction Moves
Iovance Biotherapeutics (NASDAQ: IOVA) has seen its stock rise by 8.9% following promising clinical results and strategic leadership moves. The company aims for global leadership in Tumor-Infiltrating Lymphocytes (TIL) therapies, with new non-executive hires receiving induction grants of stock. Despite some financial challenges, these strategic actions intend to instill investor confidence and position the firm as a pioneer in cancer treatment innovation.
IOVA Shares Jump 8% — What’s Retail Expecting?
Shares of Iovance Biotherapeutics Inc. (IOVA) rose 8% due to retail investor anticipation of positive announcements and potential takeover bids. The company, which specializes in tumor-infiltrating lymphocyte (TIL) therapies, reported strong product revenue for Q3 and expects significant full-year 2025 revenue from Amtagvi sales. Retail sentiment on Stocktwits remained bullish, with high message volume focusing on upcoming updates and M&A opportunities.
How Investors Are Reacting To Iovance Biotherapeutics (IOVA) FDA Boost For Its TIL Cancer Platform
Iovance Biotherapeutics (IOVA) has received positive FDA designations and reported promising clinical trial results for its Tumor Infiltrating Lymphocyte (TIL) therapy platform, strengthening confidence in its immuno-oncology approach, particularly for lung cancer. Despite these positive developments and the potential for long-term commercial opportunities, the company faces challenges including heavy losses, frequent equity issuance, a compressed share price, and a cash runway of less than a year. Investors are advised to consider various perspectives and the company's financing and execution risks before making investment decisions, as fair value estimates for the stock vary widely.
How Investors Are Reacting To Iovance Biotherapeutics (IOVA) FDA Boost For Its TIL Cancer Platform
Iovance Biotherapeutics recently reported positive clinical trial results and secured favorable FDA designations for its Tumor Infiltrating Lymphocyte (TIL) therapy platform, enhancing confidence in its immuno-oncology strategy, particularly for lung cancer. Despite these advances, the company faces ongoing financial challenges including heavy losses, frequent equity issuance, and a limited cash runway, prompting investors to closely scrutinize its financing and execution risks. The article highlights divergent fair value estimates from analysts, underscoring the uncertainty surrounding Iovance's future performance.
Advanced Melanoma Pipeline Expands With 60+ Investigational
DelveInsight's report highlights an expanding pipeline for advanced melanoma treatments, with over 55 pharmaceutical and biotech companies developing more than 60 investigational therapies. The report details promising candidates like Replimune's RP1, IO Biotech's IO102-IO103, BioNTech SE's BNT111, Perspective Therapeutics' VMT01, and Agenus Inc.'s Botensilimab, underscoring advancements in immunotherapies, targeted agents, and personalized medicine for this aggressive cancer. Key insights include in-depth profiling of companies and therapies across various development stages, as well as an analysis of market drivers and challenges.
Assessing Iovance Biotherapeutics (IOVA) Valuation After Clinical Trial Progress And New FDA Designations
Iovance Biotherapeutics (IOVA) is gaining investor attention following promising clinical trial results and favorable FDA designations for its Tumor Infiltrating Lymphocyte platform, despite a recent 60.07% decline in its one-year shareholder return. Analysts project a fair value of $8.35, suggesting a 71.7% undervaluation, driven by expectations of aggressive revenue growth, a shift to profitability, and high future earnings multiples. However, this valuation is contingent on avoiding regulatory setbacks and pricing pressures for its product, Amtagvi.
IOVA: Lung Cancer Trial Progress Will Drive Bullish Repricing Ahead
Iovance Biotherapeutics (IOVA) has reaffirmed its 2025 revenue guidance and reported positive interim Phase 2 trial data for lifileucel monotherapy in advanced nonsquamous NSCLC, showing an objective response rate of 25.6% and a 71.8% disease control rate. Despite this progress, analysts have maintained a steady price target of US$8.35, with only minor adjustments to valuation inputs rather than a fundamental shift in outlook. The company's fair value remains unchanged, indicating that current market assessment has not yet fully incorporated the potential impact of the trial results.
IOVA - Iovance Biotherp Latest Stock News & Market Updates
This page provides the latest news and analysis for Iovance Biotherapeutics (IOVA), focusing on company announcements, clinical updates, regulatory developments, and financial disclosures related to its TIL cell therapy platform. It covers news about Amtagvi, clinical trial data, corporate financial results, and insider stock option grants. The content aims to keep investors and traders informed on Iovance's progress in advancing immuno-oncology therapies.
Analyst Boosts Iovance’s Price Target Amid Positive Market Moves
Iovance Biotherapeutics Inc.'s stock surged 6.31% following promising clinical trial results and FDA designations, prompting Barclays analyst Etzer Darout to raise the price target from $9 to $10 while maintaining an Overweight rating. Despite current financial challenges, including a net loss of $91M and high operating costs, the company's comfortable debt-to-equity ratio and strategic employee stock options reflect investor confidence in its future potential and growth trajectory within the competitive biotechnology landscape.
Biotech Iovance offers 97,710 stock options to 17 new hires at $2.22
Iovance Biotherapeutics (NASDAQ: IOVA) approved inducement stock option grants for 97,710 shares to 17 new non-executive employees on January 15, 2026. Each option has an exercise price of $2.22 and vests over three years, with one-third vesting on the first anniversary of the employee’s start date and the remainder in quarterly installments. This initiative aligns with the company's past practices of using equity to attract talent and its ongoing efforts in clinical and financial milestones.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics, Inc. announced the grant of inducement stock options covering 97,710 shares of its common stock to 17 new, non-executive employees on January 15, 2026. These awards were made under the company's Amended and Restated 2021 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $2.22 and vests over a three-year period.
Iovance Biotherapeutics Stock Surges Amid Strategic Moves
Iovance Biotherapeutics' stock surged by 7.21% following promising FDA designations and strategic corporate moves, including Barclays raising its price target to $10. The company is attracting and retaining talent through inducement stock options, vesting over three years, which aims to align employee interests with shareholder value. Despite lingering losses, Iovance maintains financial resilience with $67.46M in quarterly revenues and $164.1M in cash reserves, suggesting an optimistic outlook for future growth as it balances internal investments and market positioning.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has granted inducement stock options for 97,710 shares of its common stock to 17 new non-executive employees. These awards, granted on January 15, 2026, were made under Iovance’s Amended and Restated 2021 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4) and have an exercise price of $2.22 per share. The stock options vest over a three-year period, contingent on continued employment.
Iovance Biotherapeutics (IOVA) Is Down 14.9% After Governance Scrutiny And Equity Raise Plan Is Revealed
Iovance Biotherapeutics (IOVA) has seen its stock drop by 14.9% following a shareholder investigation into past disclosure issues regarding Amtagvi's commercial performance. Despite this scrutiny and a plan for ongoing equity issuance, the company reaffirmed its 2025 revenue guidance, citing strong real-world response rates for Amtagvi in advanced melanoma and improved manufacturing efficiency. The article highlights the tension between management's confidence in its Tumor Infiltrating Lymphocyte platform's long-term potential and market skepticism concerning commercialization, governance, and capital allocation.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of "Hold" by Analysts
Iovance Biotherapeutics (NASDAQ:IOVA) has received an average rating of "Hold" from fifteen analysts, with six "buy" recommendations, seven "hold" recommendations, and two "sell" recommendations, and an average 12-month price target of $11.10. The company's shares opened at $2.45, down approximately 6.3%, and have a market capitalization of $970.6 million. Although Iovance slightly beat quarterly EPS estimates, it missed revenue expectations, and institutional investors own about 77.03% of the shares.
The Bull Case For Iovance Biotherapeutics (IOVA) Could Change Following Reaffirmed 2025 Guidance And TIL Scale-Up
Iovance Biotherapeutics (IOVA) recently reaffirmed its 2025 revenue guidance of US$250 million to US$300 million and announced that its tumor-infiltrating lymphocyte (TIL) therapies have treated over 1,000 patients globally, with manufacturing scaled to support up to 5,000 patients annually. This update reinforces the company's commitment to expanding its TIL therapy footprint and supports its near-term commercialization goals. The article highlights that while these developments strengthen Iovance's investment narrative, risks related to product dependence, international approvals, and manufacturing complexity remain.
Assessing Iovance Biotherapeutics (IOVA) Valuation After Revenue Guidance And 1,000 Patient Milestone
Iovance Biotherapeutics (IOVA) has reiterated its 2025 revenue guidance of US$250-300 million and reached a milestone of treating over 1,000 patients with its therapies. Despite recent share price momentum, the company has experienced significant long-term declines. Analysts consider IOVA undervalued with a fair value of $8.35, though its P/S ratio is slightly above a fair ratio and its market ratios send mixed signals compared to peers and the broader biotech industry.
Iovance Highlights Amtagvi Momentum and Confirms 2025 Guidance
Iovance Biotherapeutics (IOVA) has reiterated its full-year 2025 revenue guidance of $250 million to $300 million for Amtagvi sales, following strong commercial momentum. The company reported approximately $340 million in total revenue since Q1 2024 and highlighted its leadership in TIL-based cell therapy with Amtagvi demonstrating real-world response rates of about 50% in advanced melanoma. Despite weak financial performance noted by TipRanks' AI Analyst, the company is positioned for future growth through ongoing trials and improving gross margins.
Iovance Highlights Amtagvi Momentum and Confirms 2025 Guidance
Iovance Biotherapeutics announced it expects to meet its previously disclosed full-year 2025 revenue guidance of $250 million to $300 million for Amtagvi sales. The company highlighted strong commercial momentum with approximately $340 million in total revenue since Q1 2024 and significant cash on hand, alongside leadership in TIL-based cell therapy and ongoing clinical trials for future growth. Analysts currently rate IOVA as a Buy with a $14 price target, while TipRanks' AI Analyst, Spark, rates it Neutral due to financial performance concerns despite positive clinical and commercial progress.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
Pomerantz LLP has filed a class action lawsuit against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) for alleged securities fraud, following a significant drop in its stock price. This decline occurred after Iovance revised its full fiscal year 2025 total product revenue guidance downward by over 40% due to "recent launch dynamics" affecting its lead product candidate, Amtagvi. Investors who purchased Iovance securities during the Class Period have until July 14, 2025, to seek appointment as Lead Plaintiff.
Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review
Barclays analyst Etzer Darout has raised the price target for Iovance Biotherapeutics (NASDAQ: IOVA) to $10 from $9, maintaining an Overweight rating, as part of the firm's 2026 biotech sector projections. This adjustment follows Iovance's strong Q3 2025 product revenue of $68 million, driven by Amtagvi sales, and the company's optimistic forecast for Amtagvi reaching over $1 billion in peak US sales for advanced melanoma. Iovance also plans to centralize manufacturing in early 2026 to improve margins and is pursuing a larger market in non-small cell lung cancer.
Barclays adjusts valuation targets for Iovance Biotherapeutics (IOVA) amid biotech sector review
Barclays has updated its valuation targets for Iovance Biotherapeutics (IOVA) as part of a broader review of the biotech sector. This adjustment reflects Barclays' current assessment of the company's financial prospects and market position within the industry. The specific details of the new targets and the rationale behind them are part of the larger sector analysis.
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street
This article discusses two biotechnology companies, Intellia Therapeutics (NTLA) and Iovance Biotherapeutics (IOVA), whose stocks have significantly underperformed the market but are projected by some Wall Street analysts to soar by 2026. Despite potential upside, the author highlights substantial risks and challenges for both companies, including clinical setbacks, complex commercial paths, and profitability concerns, suggesting they may not be attractive long-term investments.
Fraud Investigation: Levi & Korsinsky Investigates Iovance Biotherapeutics, Inc. (IOVA) on Behalf of Shareholders
Levi & Korsinsky has launched an investigation into Iovance Biotherapeutics, Inc. (IOVA) following a significant drop in its stock price. The investigation concerns potential violations of federal securities laws after Iovance reported lower-than-expected Q1 2025 results and slashed its full-year revenue guidance. The company attributed the poor performance to manufacturing facility maintenance and lower Proleukin sales.
Is Iovance (IOVA) Turning Talent Incentives and TIL Optimism Into a Durable Competitive Edge?
Iovance Biotherapeutics Inc. (IOVA) is strengthening its position through new employee stock options and renewed optimism for its Amtagvi cell therapy and broader pipeline. This combination of talent incentives and improving sentiment around tumor-infiltrating lymphocyte (TIL) therapies, including potential expansion into non-small cell lung cancer, is positively influencing the company's long-term prospects. However, investors should be aware of the company's high cash burn and dependence on Amtagvi's commercial scaling amidst ongoing losses.
Iovance Biotherapeutics (IOVA) Stock News Today: Barclays Raises Target, Short-Interest Pressure, and 2026 Catalysts (Dec. 23, 2025)
Iovance Biotherapeutics (NASDAQ: IOVA) saw a significant stock jump on December 22, 2025, driven by a Barclays price target increase and high short interest. The article details positive analyst sentiment, routine corporate updates, and the fundamental story centered around Amtagvi's commercial scaling, margin improvement, and promising pipeline developments for 2026. However, it also highlights risks associated with commercial execution, financing, and dilution, crucial for a clinical-stage biotech.
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 8.7% - Still a Buy?
Iovance Biotherapeutics (NASDAQ:IOVA) saw its shares rise by 8.7% on Monday, closing at $2.6950 with a significant drop in trading volume. Despite this surge, analysts are divided on the company's prospects, with a consensus "Hold" rating and an average price target of $11.10. The clinical-stage biotech, which focuses on tumor-infiltrating lymphocyte (TIL) therapies, continues to report negative earnings and margins while institutional investors have been actively adjusting their positions.
Iovance Biotherapeutics: Is it Time to Invest?
Iovance Biotherapeutics (NASDAQ: IOVA) stocks recently surged by 9.48% due to FDA designations and promising results, leading Barclays to increase its price target for the company to $10 with an Overweight rating. Despite current operating losses, strategic investments, a strong current ratio, and stock options for new employees suggest a potential for future growth and a positive shift in financial performance. The article emphasizes disciplined, data-driven trading decisions over emotional ones when considering investment in volatile markets.
Iovance Biotherapeutics, Inc. $IOVA Position Increased by Squarepoint Ops LLC
Squarepoint Ops LLC significantly increased its stake in Iovance Biotherapeutics (NASDAQ:IOVA) by 115.2% in Q2, bringing its total to 856,569 shares valued at $1.47 million. While analysts have a "Hold" consensus rating with an average target price of $11.10, the company recently reported an EPS beat but missed revenue expectations, remaining unprofitable. Iovance Biotherapeutics is a clinical-stage biotechnology company focused on developing tumor-infiltrating lymphocyte (TIL) immunotherapies.
Cancer biotech offers stock options to new hires at $2.46 a share
Iovance Biotherapeutics (IOVA) has granted inducement stock options for 43,150 shares to four new non-executive employees at an exercise price of $2.46 per share. These options vest over three years, with one-third vesting after the first year and the remaining in quarterly installments over the subsequent two years, subject to continued employment. This move aims to retain talent and support the company's long-term goals in developing TIL therapies for cancer.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics announced the grant of inducement stock options covering 43,150 shares to four new non-executive employees on December 18, 2025. These awards were granted under the company's Amended and Restated 2021 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), with an exercise price of $2.46 per share. The stock options vest over a three-year period, contingent on continued employment.
